Skyhawk Therapeutics, Inc. has entered a global, five-year strategic collaboration with Celgene Corp. to discover, develop and commercialize innovative small molecule treatments for patients with neurological diseases based on Skyhawk’s STAR technology platform.   Celgene has the exclusive option to in-license worldwide intellectual property rights associated with therapeutic candidates for up to five programs with potential utility in the treatment of amyotrophic lateral sclerosis (ALS)...